Rankings
▼
Calendar
MDGL Q4 2022 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
MDGL
Madrigal Pharmaceuticals, Inc.
$10B
Q4 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$85M
Net Income
-$86M
EPS (Diluted)
$-4.98
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$59M
Free Cash Flow
-$59M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$363M
Total Liabilities
$165M
Stockholders' Equity
$197M
Cash & Equivalents
$332M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$85M
-$65M
-32.0%
Net Income
-$86M
-$65M
-33.1%
← FY 2022
All Quarters
Q1 2023 →